Pharmaceuticals

Conjugate Vaccine Market – Opportunities, Share, Growth and Competitive Analysis and Forecast 2029

September 23, 2025 by Marketing Posting

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

#How Much Will The Conjugate Vaccine Market Be Worth By 2029?#_x000D_

In recent times, the conjugate vaccine market has seen substantial growth. It is projected to expand from $18.9 billion in 2024 to $21.26 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.5%. Historical growth can be traced back to factors such as disease prevalence, government vaccination initiatives, heightened awareness, focus on paediatric vaccinations, and trends in preventive healthcare._x000D_

_x000D_

Looking into the future, the conjugate vaccine market is set to experience substantial growth and is projected to reach $33.99 billion by 2029, growing at a compound annual growth rate (CAGR) of 12.4%. Driving factors for this anticipated addendum in the forecast period include the broadening of vaccination policies, growing old-age demographics, emerging vaccine indications, issues of global health security, international alliances, and the effect of economic progress. The period’s primary trends encompass collaborations and alliances for vaccine distribution, customization for populations at greater risk, application amid rising infectious diseases, progress in vaccine production technologies, and global health endeavors for vaccine equity._x000D_

_x000D_

#Get A Free Sample Of The Report:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp_x000D_

_x000D_

#What Are The Primary Factors Supporting The Conjugate Vaccine Market Expansion?#_x000D_

The escalation in the utilization of conjugate vaccines among adults is anticipated to boost the conjugate vaccine market’s growth. Conjugate vaccines, which are formulated to incite a potent immune response to bacterial capsular polysaccharides, reinforce the body’s bacterial infection defense mechanism. Applying conjugate vaccines to adults lessens the chances of severe sickness and complications and prevents the transmission of these bacterial ailments by provoking a sturdy immune reaction. For example, as per the UK Health Security Agency (UKHSA) reports in June 2024, the ‘6-in-1’ vaccine in the UK retained a steady 91.7% coverage over 12 months. Consistent too was the first pneumococcal conjugate vaccine (PCV) dose at 93.7%. The Rotavirus coverage reported a 0.6% growth, reaching 89.3%, while the second dose of the meningitis B vaccine (MenB2) saw a slight increment of 0.1%, moving up to 91.5%. Thus, the escalating conjugate vaccine usage among adults is fueling the conjugate vaccine market’s expansion._x000D_

_x000D_

#How Is The Global Conjugate Vaccine Market Broken Down By Segment?#_x000D_

The conjugate vaccine market covered in this report is segmented – _x000D_

_x000D_

1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine_x000D_

2) By Pathogen: Bacterial, Viral_x000D_

3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid_x000D_

4) By Patient: Pediatric, Adults_x000D_

5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Monovalent Conjugate Vaccines: Single Pathogen Conjugate Vaccines_x000D_

2) By Multivalent Conjugate Vaccines: Multiple Pathogen Conjugate Vaccines, Combination Conjugate Vaccines_x000D_

_x000D_

#Which Trends Are Likely To Redefine Growth Paths In The Conjugate Vaccine Market?#_x000D_

The emergence of innovations in conjugate vaccines is a trending phenomenon being observed in the conjugate vaccine market. The companies in this market are striving to create innovative conjugate vaccines to maintain their market position. For example, in June 2022, Pfizer Inc., an American pharmaceutical and biotechnology firm, unveiled Prevnar 20, a pneumococcal 20-valent conjugate vaccine, in Canada. This vaccine is designed to safeguard adults aged 18 or older from pneumonia and serious pneumococcal infections. Prevnar 20 features conjugates for the 13 serotypes already included in PREVNAR 13, along with conjugates for seven other serotypes linked to severe pneumococcal diseases, high mortality rates, antibiotic resistance, and meningitis._x000D_

_x000D_

#Which Firms Are Making The Biggest Impact In The Conjugate Vaccine Market?#_x000D_

Major companies operating in the conjugate vaccine market include Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus _x000D_

_x000D_

#Access The Complete Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report_x000D_

_x000D_

#Which Geographic Regions Are Creating Strong Demand In The Conjugate Vaccine Market?#_x000D_

North America was the largest region in the global conjugate vaccine market in 2024. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Customize Your Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=10850&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_